Non-viral delivery platform and development services
The Hermes® nanoparticle platform offers an alternative to traditional LNP platforms by providing the unique option to include additional modalities, such as targeting ligands, via the inclusion of a cationic scaffold component.
With a cost-effective, self-assembling manufacturing process that does not require additional conjugation steps, the platform offers an efficient, high-performance solution for next-generation genetic medicines.
Flexible and scalable, the Hermes® platform offers optimisation for large transgenes, multiple payload types (DNA, RNA, gene editing), and various routes of administration, including local and IV.
Our experienced formulation team collaborates with you to design LNP formulations for your application.
Benefits of using Hermes®
Formulation stability driven by Hermes® scaffold component
Option to include additional modalities via Hermes® scaffold component
Controlled and cost-effective formulation process with no conjugation of ligands
Optimized formulations for a variety of payloads and applications, including hpDNA for DNA vaccines
What we offer
Optimized formulations for 4basebio payloads – opDNA®-derived mRNA, hpDNA and gene editing payloads – to support your cell and gene therapy and vaccine projects
Encapsulation and formulation screening services of custom payloads
LNP characterisation and in vitro validation services
Manufacture for R&D projects and pre-clinical in vivo studies
Technology
Find out more about our enzymatic manufacturing process and the benefits of synthetic DNA.
Manufacturing
Discover our RUO, HQ, and GMP-grade synthetic DNA, designed for every stage from discovery to commercial production.